Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
复制标题
DOI：
10.1186/bcr3600
复制
发表时间：
2014-01-22
期刊：
影响因子：
--
通讯作者：
Chambers AF
中科院分区：
文献类型：
--
作者：
Bramwell VH;Tuck AB;Chapman JA;Anborgh PH;Postenka CO;Al-Katib W;Shepherd LE;Han L;Wilson CF;Pritchard KI;Pollak MN;Chambers AF
骨桥蛋白 (OPN) 是一种与恶性肿瘤相关的糖蛋白，在功能上有助于肿瘤侵袭性。在转移性乳腺癌中，我们之前证明原发肿瘤和血液中 OPN 升高与预后不良相关。在一项随机试验中，我们通过 ELISA 测量了血浆中的 OPN，并通过免疫组织化学测量了肿瘤中的 OPN，分别对 667 名患有激素反应性早期乳腺癌的绝经后妇女中的 624 名 (94%) 和 462 名 (69%) 进行了手术治疗，随后用他莫昔芬+/-奥曲肽辅助治疗（NCIC CTG MA.14；加拿大国家癌症研究所临床试验组乳腺.14）。测量了 2,540 个样本的血浆 OPN；基线时收集了 688 份，随访期间收集了 1,852 份。平均基线血浆 OPN 为 46 ng/ml（范围 22.6 至 290），与正常水平没有差异。 OPN 肿瘤细胞阳性平均百分比为 33.9（95% CI：30.2 至 37.9）。血浆和肿瘤 OPN 值之间没有相关性。在多变量分析中，两者均与无事件生存期 (EFS)、无复发生存期 (RFS)、总生存期 (OS)、骨 RFS 或非骨 RFS 相关。对复发患者的探索性分析显示，与基线水平相比，复发期平均 OPN 血浆水平较高，为 60.7 ng/ml（23.9 至 543）。 OPN 肿瘤表达在早期乳腺癌中具有独立预后价值的假设并未得到该研究人群的多变量分析的支持。在 MA.14 试验中，患有激素反应性早期乳腺癌的女性的血浆 OPN 水平并未升高，并且没有证据表明血浆 OPN 在该定义的患者组中具有预后价值。然而，我们发现复发时平均 OPN 血浆水平升高，值得进一步研究。 NCT00002864，http://clinicaltrials.gov/show/NCT00002864
Osteopontin (OPN) is a malignancy-associated glycoprotein that contributes functionally to tumor aggressiveness. In metastatic breast cancer, we previously demonstrated that elevated OPN in primary tumor and blood was associated with poor prognosis. We measured OPN in plasma by ELISA, and in tumors by immunohistochemistry, in 624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/− octreotide in a randomized trial (NCIC CTG MA.14; National Cancer Institute of Canada Clinical Trials Group Mammary.14). Plasma OPN was measured in 2,540 samples; 688 at baseline and 1,852 collected during follow-up. Mean baseline plasma OPN was 46 ng/ml (range 22.6 to 290) which did not differ from normal levels. Mean percentage OPN tumor cell positivity was 33.9 (95% CI: 30.2 to 37.9). There was no correlation between plasma and tumor OPN values. In multivariate analysis, neither was associated with event-free survival (EFS), relapse-free survival (RFS), overall survival (OS), bone RFS or non-bone RFS. An exploratory analysis in patients with recurrence showed higher mean OPN plasma levels 60.7 ng/ml (23.9 to 543) in the recurrence period compared with baseline levels. The hypothesis that OPN tumor expression would have independent prognostic value in early breast cancer was not supported by multivariate analysis of this study population. Plasma OPN levels in women with hormone responsive early breast cancer in the MA.14 trial were not elevated and there was no evidence for prognostic value of plasma OPN in this defined group of patients. However, our finding of elevated mean OPN plasma level around the time of recurrence warrants further study. NCT00002864, http://clinicaltrials.gov/show/NCT00002864
登录
查看更多内容
影响因子：
8.8
作者：
Thoms, J. W.;Dal Pra, A.;Anborgh, P. H.;Christensen, E.;Fleshner, N.;Menard, C.;Chadwick, K.;Milosevic, M.;Catton, C.;Pintilie, M.;Chambers, A. F.;Bristow, R. G.
通讯作者：
Bristow, R. G.
影响因子：
11.5
作者：
Bramwell, Vivien H. C.;Doig, Gordon S.;Chambers, Ann F.
通讯作者：
Chambers, Ann F.
影响因子：
8.8
作者：
Rittling, SR;Chambers, AF
通讯作者：
Chambers, AF
DOI：
10.1093/jnci/85.3.200
发表时间：
1993-02-03
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
ALLRED, DC;CLARK, GM;MCGUIRE, WL
通讯作者：
MCGUIRE, WL
DOI：
10.2174/1566524013363339
发表时间：
2001-11-01
期刊：
Current Molecular Medicine (Hilversum)
影响因子：
--
作者：
Furger, Kara A.;Menon, Rajashree K.;Chambers, Ann F.
通讯作者：
Chambers, Ann F.